Comments
Loading...

Guardant Health Analyst Ratings

GHNASDAQ
Logo brought to you by Benzinga Data
$40.67
0.210.52%
At close: -
$40.67
0.000.00%
After Hours: May 16, 4:01 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$73.00
Lowest Price Target1
$32.00
Consensus Price Target1
$53.15

Guardant Health Analyst Ratings and Price Targets | NASDAQ:GH | Benzinga

Guardant Health Inc has a consensus price target of $53.15 based on the ratings of 28 analysts. The high is $73 issued by Morgan Stanley on February 21, 2023. The low is $32 issued by Jefferies on June 3, 2024. The 3 most-recent analyst ratings were released by Piper Sandler, Scotiabank, and Canaccord Genuity on May 6, 2025, May 5, 2025, and May 1, 2025, respectively. With an average price target of $60.67 between Piper Sandler, Scotiabank, and Canaccord Genuity, there's an implied 49.17% upside for Guardant Health Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
3
Jan
7
Feb
2
Mar
2
Apr
6
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler
Scotiabank
Canaccord Genuity
Stifel
Barclays

1calculated from analyst ratings

Analyst Ratings for Guardant Health

Buy NowGet Alert
05/06/2025Buy Now47.53%Piper Sandler
David Westenberg58%
$50 → $60MaintainsOverweightGet Alert
05/05/2025Buy Now40.15%Scotiabank
Sung Ji Nam44%
$52 → $57MaintainsSector OutperformGet Alert
05/01/2025Buy Now59.82%Canaccord Genuity
Kyle Mikson36%
$60 → $65MaintainsBuyGet Alert
05/01/2025Buy Now47.53%Stifel
Daniel Arias77%
$53 → $60MaintainsBuyGet Alert
05/01/2025Buy Now47.53%Barclays
Luke Sergott50%
$55 → $60MaintainsOverweightGet Alert
05/01/2025Buy Now47.53%TD Securities
Dan Brennan61%
$56 → $60MaintainsBuyGet Alert
05/01/2025Buy Now72.12%UBS
Dan Leonard55%
$65 → $70MaintainsBuyGet Alert
04/10/2025Buy Now35.23%Barclays
Luke Sergott50%
$60 → $55MaintainsOverweightGet Alert
04/10/2025Buy Now35.23%Mizuho
Anthony Petrone63%
→ $55Initiates → OutperformGet Alert
03/26/2025Buy Now35.23%Stephens & Co.
Mason Carrico39%
$55 → $55ReiteratesOverweight → OverweightGet Alert
03/06/2025Buy Now27.86%Morgan Stanley
Shannon O'Callaghan51%
$42 → $52MaintainsOverweightGet Alert
02/26/2025Buy Now22.94%Piper Sandler
David Westenberg58%
$34 → $50MaintainsOverweightGet Alert
02/24/2025Buy Now37.69%Guggenheim
Subbu Nambi43%
$56 → $56ReiteratesBuy → BuyGet Alert
02/24/2025Buy Now27.86%Scotiabank
Sung Ji Nam44%
$47 → $52MaintainsSector OutperformGet Alert
02/24/2025Buy Now47.53%Canaccord Genuity
Kyle Mikson36%
$42 → $60MaintainsBuyGet Alert
02/21/2025Buy Now37.69%Goldman Sachs
Matthew Sykes62%
$49 → $56MaintainsBuyGet Alert
02/21/2025Buy Now45.07%Raymond James
Andrew Cooper53%
$39 → $59ReiteratesOutperform → OutperformGet Alert
02/21/2025Buy Now35.23%JP Morgan
Rachel Vatnsdal65%
$50 → $55MaintainsOverweightGet Alert
02/21/2025Buy Now30.32%Stifel
Daniel Arias77%
$45 → $53MaintainsBuyGet Alert
01/28/2025Buy Now20.48%Goldman Sachs
Matthew Sykes62%
$36 → $49MaintainsBuyGet Alert
01/23/2025Buy Now47.53%Barclays
Luke Sergott50%
→ $60Initiates → OverweightGet Alert
01/22/2025Buy Now—Guggenheim
Subbu Nambi43%
—ReiteratesBuy → BuyGet Alert
11/07/2024Buy Now22.94%JP Morgan
Julia Qin59%
$48 → $50MaintainsOverweightGet Alert
11/07/2024Buy Now-11.48%Goldman Sachs
Matthew Sykes62%
$32 → $36MaintainsBuyGet Alert
10/30/2024Buy Now-13.94%Bernstein
Eve Burstein42%
$40 → $35MaintainsOutperformGet Alert
10/17/2024Buy Now22.94%Leerink Partners—$60 → $50MaintainsOutperformGet Alert
08/21/2024Buy Now-1.65%UBS
Dan Leonard55%
$32 → $40MaintainsBuyGet Alert
08/13/2024Buy Now-16.4%Piper Sandler
David Westenberg58%
$30 → $34MaintainsOverweightGet Alert
08/08/2024Buy Now10.65%Citigroup
Patrick Donnelly80%
$40 → $45MaintainsBuyGet Alert
08/08/2024Buy Now3.27%TD Cowen
Dan Brennan61%
$41 → $42MaintainsBuyGet Alert
08/08/2024Buy Now-9.02%Craig-Hallum
Alex Nowark61%
$28 → $37MaintainsBuyGet Alert
08/08/2024Buy Now18.02%JP Morgan
Julia Qin59%
$45 → $48MaintainsOverweightGet Alert
07/30/2024Buy Now22.94%BTIG
Mark Massaro71%
$45 → $50MaintainsBuyGet Alert
07/18/2024Buy Now-1.65%B of A Securities
Michael Ryskin46%
$28 → $40MaintainsBuyGet Alert
07/17/2024Buy Now-21.32%Goldman Sachs
Matthew Sykes62%
$28 → $32MaintainsBuyGet Alert
06/28/2024Buy Now-11.48%Guggenheim
Subbu Nambi43%
→ $36UpgradeNeutral → BuyGet Alert
06/04/2024Buy Now-6.57%Canaccord Genuity
Kyle Mikson36%
$30 → $38MaintainsBuyGet Alert
06/03/2024Buy Now-21.32%Jefferies
Tycho Peterson83%
→ $32Initiates → BuyGet Alert
05/24/2024Buy Now8.19%Stephens & Co.
Mason Carrico39%
$44 → $44ReiteratesOverweight → OverweightGet Alert
04/29/2024Buy Now-26.24%Canaccord Genuity
Kyle Mikson36%
$45 → $30MaintainsBuyGet Alert
04/24/2024Buy Now-31.15%Craig-Hallum
Alex Nowark61%
→ $28Assumes → BuyGet Alert
04/15/2024Buy Now-31.15%Goldman Sachs
Matthew Sykes62%
$32 → $28MaintainsBuyGet Alert
04/05/2024Buy Now—Guggenheim
Subbu Nambi43%
—Reiterates → NeutralGet Alert
02/26/2024Buy Now-26.24%Piper Sandler
David Westenberg58%
$40 → $30MaintainsOverweightGet Alert
02/23/2024Buy Now10.65%JP Morgan
Julia Qin59%
$60 → $45MaintainsOverweightGet Alert
02/23/2024Buy Now10.65%Canaccord Genuity
Kyle Mikson36%
$50 → $45MaintainsBuyGet Alert
01/30/2024Buy Now-9.02%Goldman Sachs
Matthew Sykes62%
$43 → $37MaintainsBuyGet Alert
01/29/2024Buy Now-9.02%Goldman Sachs
Matthew Sykes62%
$43 → $37MaintainsBuyGet Alert
12/14/2023Buy Now—Guggenheim
Subbu Nambi43%
—Initiates → NeutralGet Alert
12/13/2023Buy Now—Wolfe Research
Doug Schenkel71%
—Initiates → Peer PerformGet Alert
11/13/2023Buy Now-33.61%Raymond James
Andrew Cooper53%
→ $27UpgradeMarket Perform → OutperformGet Alert
11/08/2023Buy Now22.94%Morgan Stanley
Shannon O'Callaghan51%
$55 → $50MaintainsOverweightGet Alert
10/23/2023Buy Now10.65%Goldman Sachs
Matthew Sykes62%
$52 → $45MaintainsBuyGet Alert
10/20/2023Buy Now10.65%Goldman Sachs
Matthew Sykes62%
$52 → $45MaintainsBuyGet Alert
10/02/2023Buy Now22.94%Citigroup
Patrick Donnelly80%
$50 → $50ReiteratesBuy → BuyGet Alert
09/28/2023Buy Now-16.4%Bernstein
Eve Burstein42%
→ $34Initiates → OutperformGet Alert
09/27/2023Buy Now-1.65%Piper Sandler
David Westenberg58%
→ $40UpgradeNeutral → OverweightGet Alert
08/08/2023Buy Now-1.65%Piper Sandler
David Westenberg58%
$30 → $40MaintainsNeutralGet Alert
08/07/2023Buy Now35.23%Morgan Stanley
Shannon O'Callaghan51%
$60 → $55MaintainsOverweightGet Alert
08/04/2023Buy Now22.94%Citigroup
Patrick Donnelly80%
$40 → $50MaintainsBuyGet Alert
05/26/2023Buy Now-1.65%Citigroup
Patrick Donnelly80%
→ $40UpgradeNeutral → BuyGet Alert
05/11/2023Buy Now47.53%Morgan Stanley
Shannon O'Callaghan51%
$66 → $60MaintainsOverweightGet Alert
05/10/2023Buy Now35.23%Credit Suisse
Dan Leonard55%
$60 → $55MaintainsOutperformGet Alert
05/01/2023Buy Now—OTR Global——DowngradeMixed → NegativeGet Alert
03/09/2023Buy Now-18.86%Citigroup
Patrick Donnelly80%
$60 → $33DowngradeBuy → NeutralGet Alert
03/03/2023Buy Now-13.94%Piper Sandler
David Westenberg58%
$50 → $35MaintainsNeutralGet Alert
02/27/2023Buy Now62.28%Morgan Stanley
Shannon O'Callaghan51%
$73 → $66MaintainsOverweightGet Alert
02/24/2023Buy Now22.94%BTIG
Mark Massaro71%
$60 → $50MaintainsBuyGet Alert
02/24/2023Buy Now47.53%Canaccord Genuity
Kyle Mikson36%
$65 → $60MaintainsBuyGet Alert
02/24/2023Buy Now30.32%Cowen & Co.
Max Masucci27%
$70 → $53MaintainsOutperformGet Alert
02/24/2023Buy Now59.82%JP Morgan
Julia Qin59%
$75 → $65MaintainsOverweightGet Alert
02/24/2023Buy Now47.53%Credit Suisse
Dan Leonard55%
$70 → $60MaintainsOutperformGet Alert
02/21/2023Buy Now79.49%Morgan Stanley
Tejas Savant50%
$80 → $73MaintainsOverweightGet Alert
02/16/2023Buy Now54.91%Stephens & Co.
Mason Carrico39%
→ $63Reiterates → OverweightGet Alert
02/06/2023Buy Now10.65%Goldman Sachs
Matthew Sykes62%
$70 → $45MaintainsBuyGet Alert
01/05/2023Buy Now-11.48%Scotiabank
Sung Ji Nam44%
→ $36Initiates → Sector OutperformGet Alert
11/18/2022Buy Now109%JP Morgan
Julia Qin59%
$100 → $85MaintainsOverweightGet Alert
11/07/2022Buy Now121.29%Stephens & Co.
Mason Carrico39%
$99 → $90MaintainsOverweightGet Alert
11/04/2022Buy Now72.12%Goldman Sachs
Matthew Sykes62%
$80 → $70MaintainsBuyGet Alert
11/04/2022Buy Now72.12%Credit Suisse
Dan Leonard55%
$80 → $70MaintainsOutperformGet Alert
11/01/2022Buy Now22.94%Piper Sandler
David Westenberg58%
$65 → $50DowngradeOverweight → NeutralGet Alert
10/19/2022Buy Now116.38%Craig-Hallum
Alex Nowark61%
→ $88Initiates → BuyGet Alert
10/06/2022Buy Now143.42%Stephens & Co.
Mason Carrico39%
→ $99Initiates → OverweightGet Alert
08/25/2022Buy Now96.71%Credit Suisse
Dan Leonard55%
→ $80Initiates → OutperformGet Alert
08/08/2022Buy Now96.71%Morgan Stanley
Tejas Savant50%
$85 → $80MaintainsOverweightGet Alert
08/08/2022Buy Now96.71%Goldman Sachs
Matthew Sykes62%
$90 → $80MaintainsBuyGet Alert
06/03/2022Buy Now59.82%Piper Sandler
David Westenberg58%
→ $65Initiates → OverweightGet Alert

FAQ

Q

What is the target price for Guardant Health (GH) stock?

A

The latest price target for Guardant Health (NASDAQ:GH) was reported by Piper Sandler on May 6, 2025. The analyst firm set a price target for $60.00 expecting GH to rise to within 12 months (a possible 47.53% upside). 39 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Guardant Health (GH)?

A

The latest analyst rating for Guardant Health (NASDAQ:GH) was provided by Piper Sandler, and Guardant Health maintained their overweight rating.

Q

When was the last upgrade for Guardant Health (GH)?

A

The last upgrade for Guardant Health Inc happened on June 28, 2024 when Guggenheim raised their price target to $36. Guggenheim previously had a neutral for Guardant Health Inc.

Q

When was the last downgrade for Guardant Health (GH)?

A

The last downgrade for Guardant Health Inc happened on May 1, 2023 when OTR Global changed their price target from N/A to N/A for Guardant Health Inc.

Q

When is the next analyst rating going to be posted or updated for Guardant Health (GH)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Guardant Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Guardant Health was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.

Q

Is the Analyst Rating Guardant Health (GH) correct?

A

While ratings are subjective and will change, the latest Guardant Health (GH) rating was a maintained with a price target of $50.00 to $60.00. The current price Guardant Health (GH) is trading at is $40.67, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch